Dulaglutide vs Thymulin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideImmune Support
Thymulin- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Thymulin is a nonapeptide hormone produced exclusively by the thymic epithelium. It requires zinc for biological activity and plays a critical role in T-lymphocyte maturation, differentiation, and immune regulation. Thymulin levels decline dramatically with age, contributing to immunosenescence.
- Half-Life
- ~5 days
- ~30 minutes active half-life
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 20-30 mcg
- Frequency
- Once weekly
- 10 days per month (Khavinson protocol)
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Enhances T-cell maturation and differentiation
- Boosts NK cell cytotoxic activity
- Reduces inflammatory cytokine production (TNF-α, IL-1)
- Anti-nociceptive (pain-reducing) properties
- Restores age-related immune decline
- Anti-inflammatory via serotonin pathway modulation
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Injection site reactions
- Mild fatigue initially as immune system activates
- Stacks With
- —
- —